Given that the interaction of Mucin-4 and HER2 occurs in the extracellular space, similar to the mentioned p95HER2 receptor, there is a possibility that TKIs can overcome this mechanism of resistance; this has been shown with lapatinib in preclinical models of HER2+ gastric cancer [43]. This evidence concerns the gene ERBB2 and gastric cancer.